Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Payables (2016 - 2025)

Historic Payables for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $11.4 million.

  • Mimedx's Payables rose 6486.14% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 6486.14%. This contributed to the annual value of $7.4 million for FY2024, which is 1811.45% down from last year.
  • Mimedx's Payables amounted to $11.4 million in Q3 2025, which was up 6486.14% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Payables ranged from a high of $11.4 million in Q3 2025 and a low of $6.9 million during Q3 2021
  • Over the past 5 years, Mimedx's median Payables value was $8.2 million (recorded in 2023), while the average stood at $8.4 million.
  • As far as peak fluctuations go, Mimedx's Payables crashed by 2901.8% in 2021, and later soared by 6486.14% in 2025.
  • Mimedx's Payables (Quarter) stood at $7.4 million in 2021, then grew by 14.48% to $8.5 million in 2022, then increased by 7.03% to $9.0 million in 2023, then dropped by 18.11% to $7.4 million in 2024, then surged by 54.07% to $11.4 million in 2025.
  • Its Payables was $11.4 million in Q3 2025, compared to $8.5 million in Q2 2025 and $8.9 million in Q1 2025.